Immunocore Holdings plc (IMCR)
| Previous close | 54.74 |
| Open | 54.52 |
| Bid | 51.88 x 100 |
| Ask | 55.85 x 200 |
| Day's range | 54.52 - 54.52 |
| 52-week range | 42.21 - 76.98 |
| Volume | |
| Avg. volume | 501,183 |
| Market cap | 2.658B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.41 |
| Earnings date | 08 May 2024 - 12 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 85.40 |
GlobeNewswireImmunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor confere
- GlobeNewswire
Immunocore presented two posters at CROI 2024
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 05 March 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases,
Simply Wall St.Immunocore Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Immunocore Holdings ( NASDAQ:IMCR ) Full Year 2023 Results Key Financial Results Revenue: US$249.4m (up 44% from FY...
